

Edgar Filing: Vanda Pharmaceuticals Inc. - Form SC 13G/A

Vanda Pharmaceuticals Inc.
Form SC 13G/A
January 21, 2010

CUSIP No. 921659 10 8

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 1)¹

Vanda Pharmaceuticals Inc.
(Name of Issuer)

Common Stock, \$.01 par value
(Title of Class of Securities)

921659 10 8
(CUSIP Number)

December 31, 2009
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is Filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

Edgar Filing: Vanda Pharmaceuticals Inc. - Form SC 13G/A

¹The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

Edgar Filing: Vanda Pharmaceuticals Inc. - Form SC 13G/A

CUSIP No. 921659 10 8

| | | | |
|-----|----------------------------------------|-----------------------------------------|-----|
| 1) | Name of Reporting Person | Domain Partners VI, L.P. | |
| | I.R.S. Identification | | |
| | No. of Above Person | | |
| | (Entities Only) | | |
| 2) | Check the Appropriate Box | (a) <input checked="" type="checkbox"/> | |
| | if a Member of a Group | (b) <input type="checkbox"/> | |
| 3) | SEC Use Only | | |
| 4) | Citizenship or Place | Delaware | |
| | of Organization | | |
| | Number of | 5) Sole Voting | |
| | Shares Beneficially | Power | -0- |
| | Owned by Each | 6) Shared Voting | |
| | Reporting Person | Power | -0- |
| | With | 7) Sole Dispositive | |
| | | Power | -0- |
| | | 8) Shared Dispositive Power | |
| | | | -0- |
| 9) | Aggregate Amount Beneficially Owned | | -0- |
| | by Each Reporting Person | | |
| 10) | Check if the Aggregate Amount in Row | | |
| | (9) Excludes Certain Shares | | |
| 11) | Percent of Class Represented by Amount | | -0- |
| | in Row (9) | | |
| 12) | Type of Reporting Person | PN | |

Edgar Filing: Vanda Pharmaceuticals Inc. - Form SC 13G/A

CUSIP No. 921659 10 8

| | | | |
|-----|----------------------------------------|-----------------------------------------|-----|
| 1) | Name of Reporting Person | DP VI Associates, L.P. | |
| | I.R.S. Identification | | |
| | No. of Above Person | | |
| | (Entities Only) | | |
| 2) | Check the Appropriate Box | (a) <input checked="" type="checkbox"/> | |
| | if a Member of a Group | (b) <input type="checkbox"/> | |
| 3) | SEC Use Only | | |
| 4) | Citizenship or Place | Delaware | |
| | of Organization | | |
| | Number of | 5) Sole Voting | |
| | Shares Beneficially | Power | -0- |
| | Owned by Each | 6) Shared Voting | |
| | Reporting Person | Power | -0- |
| | With | 7) Sole Dispositive | |
| | | Power | -0- |
| | | 8) Shared Dispositive Power | |
| | | | -0- |
| 9) | Aggregate Amount Beneficially Owned | | -0- |
| | by Each Reporting Person | | |
| 10) | Check if the Aggregate Amount in Row | | |
| | (9) Excludes Certain Shares | | |
| 11) | Percent of Class Represented by Amount | | -0- |
| | in Row (9) | | |
| 12) | Type of Reporting Person | PN | |

Edgar Filing: Vanda Pharmaceuticals Inc. - Form SC 13G/A

CUSIP No. 921659 10 8

Amendment No. 1 to Schedule 13G (Final Amendment)

Reference is hereby made to the statement on Schedule 13G filed with the Securities and Exchange Commission on February 12, 2007 (the "Schedule 13G"). Terms defined in the Schedule 13G are used herein as so defined.

The following Items of the Schedule 13G are hereby amended and restated to read as follows:

Item 4 Ownership.

(a) Amount Beneficially Owned:

Domain VI: -0-
DP VI A: -0-

(b) Percent of Class:

Domain VI: -0-
DP VI A: -0-

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote:

Domain VI: -0-
DP VI A: -0-

(ii) shared power to vote or to direct the vote: -0-

(iii) sole power to dispose or to direct the disposition of:

Domain VI: -0-
DP VI A: -0-

(iv) shared power to dispose or to direct the disposition of: -0-

Edgar Filing: Vanda Pharmaceuticals Inc. - Form SC 13G/A

Item 5 - Ownership Of Five Percent Or Less Of A Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the Common Stock, check the following: X

Edgar Filing: Vanda Pharmaceuticals Inc. - Form SC 13G/A

CUSIP No. 921659 10 8

Signature:

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

DOMAIN PARTNERS VI, L.P.

By: One Palmer Square Associates VI, L.L.C., General Partner

By: /s/ Kathleen K. Schoemaker
Managing Member

DP VI ASSOCIATES, L.P.

By: One Palmer Square Associates VI, L.L.C., General Partner

By: /s/ Kathleen K. Schoemaker
Managing Member

Date: January 20, 2010